webinar register page

Webinar banner
State of the Science 2022 March 24 (8-9amPST//4-5pm GMT)
State of the Science is a town hall scientific discussion on select topics in Type 1 diabetes research. State of the Science is a new way of talking about research in the field of T1D. This series will be a celebration of the power of debate and discussion that women scientists in T1D research bring to the table. The final discussion in the series focuses on : Integrating Approaches to T1D cures: creating a roadmap, or a “Diabetosome” to connect interdisciplinary research.

Mar 24, 2022 08:00 AM in Pacific Time (US and Canada)

Webinar logo
* Required information
Loading

Speakers

Carmella Evans-Molina MD PhD
J.O. Ritchey Professor of Medicine/Director IDRC @Indiana University @Indiana Diabetes Research Center
Dr Evans-Molina is the J.O. Ritchey Professor of Medicine. She serves as Director of the Indiana Diabetes Research Center (IDRC) and as Director of the IDRC Islet and Physiology Core. She directs the Diabetes Research Program in the Herman B. Wells Center for Pediatric Research and is a staff physician at the Richard L. Roudebush VA Medical Center. She serves as an Associate Director of the Medical Scientist Training Program at IU. Dr. Evans-Molina is an investigator in the Type 1 Diabetes TrialNet Network, where she serves as a Scientific Advisor and as Chair of the Long-Term Investigative Follow-Up (LIFT) Study. She is also a member of the Rare and Atypical Diabetes (RADIANT) Network. Dr. Evans-Molina is a Co-Executive Director nPOD and is a Co-PI of the NIH-funded Integrated Islet Distribution Program (IIDP)
Rodica Pop-Busie MD
P.I., Metabolism, Endocrinology, Diabetes @UMICH @University of Michigan
Dr. Rodica Pop-Busui is a prominent diabetologist at Michigan Medicine in Ann Arbor, and a nationally and internationally recognized leader in the field of diabetes as a result of her extensive clinical, research, teaching, and service activities Dr. Pop-Busui took the lead in studies evaluating the natural history and the impact of metabolic memory on cardiovascular autonomic neuropathy in this cohort, and the role of cardiovascular autonomic neuropathy in the development of left ventricular dysfunction in type 1 diabetes. Most recently, Dr. Pop-Busui is the site Principal Investigator and member of the Steering Committee of the newly funded NIDDK trial "PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in Type 1 Diabetes" and site Principal Investigator in the NIDDK-funded trial "Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study (GRADE).Dr. Pop-Busui has devoted her life and career to the treatment and understanding of diabetes.
Noel Burtt PhD
Director, Operations & Development, Knowledge Portals & Diabetes Research @MIT/the Broad
Noël Burtt is the director of operations and development of the Diabetes Research & Knowledge Portals in the Medical and Population Genetics Program and Metabolism Program at the Broad Institute. Her work centers on the operational and organizational leadership of large-scale, international genetics consortia and public/private partnerships for human genetics studies, with a focus on type 2 diabetes and cardiometabolic diseases. In the Diabetes Research & Knowledge Portals, Burtt oversees the data coordination platform and efforts to serve the international diabetes genetics research community. She also stewards new collaborations and research initiatives and directs community outreach, education, and external relations for the KPN software platform for complex diseases.
Cate Speake PhD
Research Assistant Member @Benaroya Research Institute (BRI)
Dr. Cate Speake received her BS degree in Microbiology and her PhD in Pathobiology from the University of Washington in Seattle, WA. She then pursued post-doctoral studies in Systems Immunology at Benaroya Research Institute (BRI), and subsequently transitioned to the Diabetes Clinical Research Program at BRI as a staff scientist. In 2019, Dr. Speake joined the faculty at BRI and is currently a Research Assistant Member in the Center for Interventional Immunology. Working with Dr. Carla Greenbaum, she serves as the lead translational scientist in BRI’s Diabetes Clinical Research Program. She coordinates BRI’s Experimental Medicine Unit, and, with Dr. Alice Long, is principal investigator of the JDRF-funded Core for Assay Validation. She is also the project lead for BRI’s collaborative study with the Allen Institute for Immunology
Danielle Dean PhD
Assistant Professor of Medicine @Vanderbilt University Medical Center
Dr. Dean's longtime interests have been to understand how nutritional status and other environmental factors stimulate cell proliferation and affect the susceptibility of vulnerable cells to degeneration. Her current interests are the determinants of endocrine mass, specifically pancreatic islet alpha cell mass. While much effort has been focused on understanding beta cell biology because of insulin's well known role in diabetes, very little is known about signals regulating other islet cells. Alpha cells secrete glucagon in response to hypoglycemia, but persons with diabetes have hyperglucagonemia contributing to hyperglycemia. Struck by the impressive alpha cell hyperplasia and hyperglucagonemia in mice with interrupted glucagon signaling, Dr. Dean sought to identify the mechanism underlying this during her postdoctoral training. She identified that unknown circulating factors stimulate alpha cell hyperplasia in mice with interrupted glucagon signaling.
Vira Kravets PhD
Post-doctoral Fellow, HIRN Emerging Leader @CU Denver
Dr Kravtes aims to lead a multidisciplinary lab which will focus on the healthy function of the pancreas, and on pathophysiology of diabetes. She uses confocal microscopy, targeted single cell laser ablation, optogenetics, and computational modelling to study live human tissue, and zebrafish models to understand why some insulin-producing cells disproportionately control other cell. This will be applied in tissue engineering for pancreatic islet transplantation for diabetic patients.